Thea Cæcilie Viborg Vestergaard

Pregnancy outcome in four women with inflammatory bowel disease treated with budesonide MMX

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Background: Maintaining disease remission throughout pregnancy in women with inflammatory
bowel disease is of the utmost importance to decrease the risk of adverse outcome. In general, corticosteroids
are safe to use during pregnancy, but no data exist in the specific use of budesonide MMX.
We report four cases of budesonide MMX in pregnancy and pregnancy outcome.
Methods: Four women with inflammatory bowel disease experienced disease activity during pregnancy.
They were treated with budesonide MMX in an attempt to obtain clinical remission. Disease
activity was assessed through physician’s global assessment as well as lower endoscopy.
Results: Budesonide MMX proved effective in achieving remission in three out of four women. One woman
had an uncomplicated colectomy in the second trimester. All children were born normal for gestational age,
with no congenital abnormalities and have reached all their developmentalmilestones. The four children have
received vaccines according to the national immunization programwithout complications.
Conclusion: No adverse pregnancy outcomes were reported after the use of budesonide MMX. To our
knowledge, this is the first report on the safety of budesonide MMX treatment in pregnant women
with inflammatory bowel disease.
TidsskriftScandinavian Journal of Gastroenterology
Sider (fra-til)1459-1462
Antal sider4
StatusUdgivet - 2018


  • IBD, Pregnancy, Budesonide

Se relationer på Aarhus Universitet Citationsformater

ID: 140859007